SymBio Pharmaceuticals Limited
SYMQY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $47,312 | $6,126,447 | $9,287,458 | $8,725,470 |
| - Cash | $23,454 | $3,053,848 | $3,614,766 | $3,963,000 |
| + Debt | $15,845 | $1,300,000 | $700,000 | $0 |
| Enterprise Value | $39,703 | $4,372,599 | $6,372,692 | $4,762,470 |
| Revenue | $2,198 | $382,616 | $264,022 | $553,631 |
| % Growth | -99.4% | 44.9% | -52.3% | – |
| Gross Profit | $1,369 | $291,157 | $202,410 | $428,665 |
| % Margin | 62.3% | 76.1% | 76.7% | 77.4% |
| EBITDA | -$7,941 | -$6,894 | -$135,027 | -$1,061,468 |
| % Margin | -361.3% | -1.8% | -51.1% | -191.7% |
| Net Income | -$8,113 | -$1,047,709 | -$1,321,481 | -$987,976 |
| % Margin | -369.1% | -273.8% | -500.5% | -178.5% |
| EPS Diluted | -0.16 | -22.16 | -27.95 | -21.55 |
| % Growth | 99.3% | 20.7% | -29.7% | – |
| Operating Cash Flow | – | $0 | $0 | $0 |
| Capital Expenditures | – | $0 | $0 | $0 |
| Free Cash Flow | – | $0 | $0 | $0 |